Erik Schneider

Erik Schneider is a Director of Business Development at Cambrian Biopharma. Previously, Erik was on the Business Development and Licensing team at Novartis, evaluating deal and portfolio strategy across cardiovascular, immunology, and neuroscience franchises. Prior to joining Novartis, Erik was a consultant at CBPartners (now Trinity Life Sciences), with a focus on commercial and pricing strategy for new products. Erik graduated from the College of the Holy Cross with a degree in Biochemistry.